BioNTech und CEPI geben Partnerschaft zur Entwicklung eines mRNA-Mpox-Impfstoffs und zur Unterstützung von CEPIs 100-Tage-Ziel bekannt
18 sept. 2023 06h45 HE
|
BioNTech SE
BioNTech bereitet klinische Phase-1/2-Studie für das mRNA-basierte Mpox-Impfstoffprogramm BNT166 vorDie Coalition for Epidemic Preparedness Innovations (CEPI) stellt bis zu 90 Millionen US-Dollar für...
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
18 sept. 2023 06h45 HE
|
BioNTech SE
BioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness Innovations (CEPI) commits funding of up to $90 million for the...
Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program
13 sept. 2023 08h00 HE
|
Nemaura Medical, Inc
LOUGHBOROUGH, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive...
Protein Industries Canada and Innovate UK Announce Joint Call for Plant-Based Food and Ingredient R&D Projects
12 sept. 2023 12h00 HE
|
Protein Industries Canada
Edmonton, Alta., Sept. 12, 2023 (GLOBE NEWSWIRE) -- The bilateral partnership between Protein Industries Canada, one of Canada’s five Global Innovation Clusters, and Innovate UK, the UK’s national...
サリプロ・バイオテック (Salipro Biotech)、住友ファーマと研究提携を締結し、創薬プログラムを推進
12 sept. 2023 02h00 HE
|
Salipro Biotech AB
本提携では、サリプロ・バイオテックの独自の専門知識とSalipro®プラットフォーム技術を活用して困難な薬物標的を安定化し、住友ファーマの創薬プログラムによる化合物の薬理学的特性を研究 する。 スウェーデン・ストックホルム発, Sept. 12, 2023 (GLOBE NEWSWIRE) -- スウェーデンのバイオテクノロジー企業であるサリプロ・バイオテックAB (Salipro...
Salipro Biotech geht Forschungskooperation mit Sumitomo Pharma zum Vorantreiben eines Medikamentenentwicklungsprogramms ein
12 sept. 2023 02h00 HE
|
Salipro Biotech AB
Die Zusammenarbeit nutzt die einzigartige Expertise von Salipro Biotech und die Salipro®-Plattformtechnologie zur Stabilisierung eines anspruchsvollen Wirkstoffziels, um die pharmakologischen...
Salipro Biotech collabore avec Sumitomo Pharma pour développer un programme de recherche de médicaments
12 sept. 2023 02h00 HE
|
Salipro Biotech AB
La collaboration mobilise l'expertise unique de Salipro Biotech et sa plateforme technologique Salipro® pour stabiliser une cible pharmacologique difficile. Objectif : étudier les caractéristiques...
Salipro Biotech enters into research collaboration with Sumitomo Pharma to advance a drug discovery program
12 sept. 2023 02h00 HE
|
Salipro Biotech AB
The collaboration leverages Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilize a challenging drug target to investigate the pharmacological characteristics of a...
Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases
08 sept. 2023 07h00 HE
|
Verge Genomics
Verge to receive up to $42M in upfront and near-term payments, with future cumulative milestones worth up to $840M The collaboration is the second with a leading global pharmaceutical company and...
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
05 sept. 2023 07h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...